Chrysos (C79) investor relations material

Financial Performance and Guidance

• FY26 total revenue is expected to be between $80m and $90m, with EBITDA forecasted at $20m to $27m, both trending toward the upper end of guidance due to strong 1H FY26 results and high sample volumes.

• Cash on hand stands at $23.7m, with $41.1m in undrawn facilities and a $200m debt facility on track for completion before 30 June 2026.

• Additional Assay Charges (AAC) accounted for 27.1% of revenue in 1H FY26, up from 11.2% in 1H FY25, reflecting increased sample throughput.

Record Sample Processing and Network Utilisation

• PhotonAssay™ sample volumes reached over 1,000,000 in March and April 2026, setting new fleet records and highlighting increased productivity.

• Higher sample volumes are driving greater utilisation and accelerating AAC, supporting revenue and profitability growth.

Expansion of Lease Agreements and Partnerships

• 44 PhotonAssay™ units are deployed globally, with 78 contracted units and 19 new agreements signed in FY26, including expansion with major labs and miners.

• Secured two additional agreements with ALS, now totaling sixteen units, and expanded direct-to-mine presence with Allied Gold.

• Signed a second lease with Bureau Veritas for Australia, expanding the partnership after the initial South America agreement.